



Published in final edited form as:

*Gastroenterology*. 2021 October ; 161(4): 1208–1217.e9. doi:10.1053/j.gastro.2021.07.002.

## Total vitamin D intake and risks of early-onset colorectal cancer and precursors

Hanseul Kim<sup>1</sup>, Marla Lipsyc-Sharf<sup>2</sup>, Xiaoyu Zong<sup>3</sup>, Xiaoyan Wang<sup>3</sup>, Jinhee Hur<sup>4</sup>, Mingyang Song<sup>1,4,5,6</sup>, Molin Wang<sup>1,7,8</sup>, Stephanie A. Smith-Warner<sup>1,4</sup>, Charles Fuchs<sup>9</sup>, Shuji Ogino<sup>1,10,11,12</sup>, Kana Wu<sup>4</sup>, Andrew T. Chan<sup>5,8,12,13</sup>, Yin Cao<sup>3,14,15,\*</sup>, Kimmie Ng<sup>16,\*</sup>, Edward L. Giovannucci<sup>1,4,8,\*</sup>

<sup>1</sup>Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA

<sup>2</sup>Department of Internal Medicine, Brigham and Women's Hospital, Boston, MA, USA

<sup>3</sup>Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St Louis, MO, USA

<sup>4</sup>Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA

<sup>5</sup>Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

<sup>6</sup>Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

<sup>7</sup>Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA

<sup>8</sup>Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA

<sup>9</sup>Yale Cancer Center, Smilow Cancer Hospital, New Haven, CT, USA

<sup>10</sup>Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA

**Corresponding author** Edward L. Giovannucci, MD, ScD, Department of Nutrition, Harvard T.H. Chan School of Public Health, Building 2, 3rd Floor, 655 Huntington Avenue, Boston, MA 02115, USA, Phone: 617-432-4648, Fax: 617-432-2435, egiovann@hsph.harvard.edu.

**Author contributions:** Yin Cao, Kimmie Ng, and Edward L. Giovannucci contributed equally as co-last authors in this paper. The study was conceived and designed by Hanseul Kim, Yin Cao, Kimmie Ng, and Edward L. Giovannucci. Hanseul Kim analyzed and drafted the manuscript. Xiaoyu Zong checked the accuracy of the analysis. All authors revised the manuscript critically and approved the final version of the manuscript.

\*These authors contributed equally as co-last authors

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**Conflict of interest statement:** Andrew T. Chan reported receiving consulting fees from Boehringer Ingelheim, Pfizer Inc, and Bayer Pharma AG. Charles Fuchs has been a consultant and/or a scientific advisor for Eli Lilly, Entrinsic Health, Pfizer, Merck, Sanofi, Roche, Genentech, Merrimack Pharmaceuticals, Dicerna, Bayer, Celgene, Agios, Gilead Sciences, Five Prime Therapeutics, Taiho, and KEW. Kimmie Ng reported the following disclosures for the past 12 months: research funding from Pharmavite, Revolution Medicines, Janssen, and Evergrande Group; Advisory boards for Array Biopharma, Seattle Genetics, and BiomX; and consulting for X-Biotix Therapeutics. No other disclosures were reported.

**Data transparency statement:** Information including the procedures for obtaining and accessing data from the Nurses' Health Studies II is described here: [www.nurseshealthstudy.org/researchers](http://www.nurseshealthstudy.org/researchers)

<sup>11</sup>Cancer Immunology Program and Cancer Epidemiology Program, Dana-Farber Harvard Cancer Center, Boston, MA, USA

<sup>12</sup>Broad Institute of MIT and Harvard, Cambridge, MA, USA

<sup>13</sup>Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, USA

<sup>14</sup>Alvin J. Siteman Cancer Center, Washington University School of Medicine in St Louis, St Louis, MO, USA

<sup>15</sup>Division of Gastroenterology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA

<sup>16</sup>Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA

## Abstract

**Background & Aims:** Vitamin D has been implicated in colorectal cancer (CRC) pathogenesis, but it remains unknown whether total vitamin D intake is associated with early-onset CRC and precursors diagnosed before age 50.

**Methods:** We prospectively examined the association between total vitamin D intake and risks of early-onset CRC and precursors among women enrolled in the Nurses' Health Study II. Multivariable-adjusted hazard ratio (HR) and 95% confidence interval (CI) for early-onset CRC were estimated with Cox proportional hazards model. Multivariable-adjusted odds ratio (OR) and 95% CI for early-onset conventional adenoma and serrated polyp were estimated with logistic regression model.

**Results:** We documented 111 incident cases of early-onset CRC during 1,250,560 person-years of follow-up (1991 to 2015). Higher total vitamin D intake was significantly associated with a reduced risk of early-onset CRC (HR for >450 IU/day vs <300 IU/day, 0.49; 95% CI, 0.26-0.93; P for trend = 0.01). The HR per 400 IU/day increase was 0.46 (95% CI, 0.26-0.83). The inverse association was significant and appeared more evident for dietary sources of vitamin D (HR per 400 IU/day increase, 0.34; 95% CI, 0.15-0.79) than supplemental vitamin D (HR per 400 IU/day increase, 0.77; 95% CI, 0.37-1.62). For CRC precursors, the ORs per 400 IU/day increase were 0.76 (95% CI, 0.65-0.88) for conventional adenoma (n = 1,439) and 0.85 (95% CI, 0.75-0.97) for serrated polyp (n = 1,878).

**Conclusions:** In a cohort of younger women, higher total vitamin D intake was associated with decreased risks of early-onset CRC and precursors.

## Lay summary:

This large prospective cohort study suggests that higher total vitamin D intake is associated with reduced risks of early-onset colorectal cancer and precursors.

## Keywords

vitamin D; colorectal cancer; colorectal adenoma; cancer epidemiology

## INTRODUCTION

Despite a decline in the overall incidence of colorectal cancer (CRC) in many countries including the United States, the incidence of CRC in younger adults has been rising<sup>1, 2</sup>. It is projected that by 2030, almost 11% of colon cancers and 23% of rectal cancers will occur among US adults younger than age 50<sup>3</sup>. Compared to CRC diagnosed after age 50, early-onset CRC (defined as CRC diagnosed before age 50) is typically diagnosed at a more advanced stage, likely due to delays in diagnosis<sup>4</sup> and potentially more aggressive behavior relating to different clinicopathological characteristics<sup>5, 6</sup>. As a substantial proportion of early-onset CRC patients do not have a family history of CRC or known hereditary syndrome<sup>7, 8</sup>, recent changes in lifestyle factors and dietary patterns are hypothesized to contribute to the increasing incidence of early-onset CRC. Recently, researchers found a significant association between sedentary behaviors<sup>9</sup>, obesity<sup>10</sup>, and increased risk of early-onset CRC in the Nurses' Health Study II (NHS II), suggesting that at least some well-known risk factors of traditional CRC may also contribute to early-onset CRC.

Vitamin D intake represents a possible factor that may contribute to the recent increase in early-onset CRC incidence. A study reported that vitamin D intake from food sources such as fish, mushrooms, and eggs has decreased since the 1980s<sup>11</sup>. While milk is one of the primary food sources of vitamin D in the United States<sup>12</sup>, milk intake has declined over time<sup>13</sup>. Although vitamin D levels have been extensively studied as a protective factor against CRC<sup>14-19</sup>, it remains unknown whether vitamin D intake is associated with the risk of early-onset CRC.

As reducing the rising burden of early-onset CRC is a priority in CRC prevention, we sought to determine whether total vitamin D intake is associated with risk of early-onset CRC by analyzing data from the NHS II. We also assessed the relationship for CRC precursors (i.e., conventional adenomas and serrated polyps) as most CRC cases arise from adenomas<sup>20</sup> and possibly serrated polyps<sup>21-23</sup>.

## MATERIALS AND METHODS

### Study population

The NHS II is a prospective cohort study of 116,429 female nurses aged 25 to 42 years that began in 1989. Participants are followed every 2 years by self-administered questionnaires on demographics, lifestyle factors, and medical and other health-related information, which are complemented by assessments of dietary intake using validated semiquantitative Food Frequency Questionnaires (FFQ) every 4 years. The study protocol (1999-P-003389) was approved by the institutional review boards of the Brigham and Women's Hospital and Harvard T.H. Chan School of Public Health, and those of participating registries as required.

For the current analysis, we excluded women with inflammatory bowel disease, prior diagnosis of CRC, implausible data for baseline energy intake (<600 or >3500 kcal/d), or missing data for baseline vitamin D intake.

### Assessment of total vitamin D intake

Total vitamin D intake was calculated by adding dietary vitamin D intake and supplemental vitamin D intake from vitamin D-specific supplements and multivitamins. Dietary vitamin D intake was derived from the FFQs starting in 1991. The accuracy of the food and nutrient intakes from the FFQ was assessed in several validation studies. The Spearman correlation coefficient between two 7-day dietary records and 152-item FFQ was 0.60 for energy-adjusted intake of total vitamin D including supplements<sup>24</sup>. In addition, the correlations between intakes estimated from four 1-week diet records and 61-item FFQ were 0.81 for skim milk and 0.66 for fish<sup>25</sup>, which are the two major food items that contribute to vitamin D intake.

The validity of studying vitamin D intake as a predictor for circulating vitamin D was previously evaluated. The prediction model included age, race, body mass index (BMI), physical activity, alcohol intake, post-menopausal hormone use, ultraviolet-B radiation flux at residence, dietary and supplementary vitamin D intakes, and season of blood draw. In this model predicting plasma 25-hydroxyvitamin D (25(OH)D) levels in the NHS II, 400 IU/day compared to <100 IU/day of dietary vitamin D intake was associated with a 2.49 ng/mL increase in predicted plasma 25(OH)D levels and 400 IU/day compared to 0 IU/day of supplementary vitamin D intake was associated with a 2.70 ng/mL increase in 25(OH)D levels<sup>26</sup>.

### Assessment of covariates

We calculated BMI based on reported height and weight, with weight updated every 2 years. We assessed total energy, red meat, processed meat, fiber, calcium, folate, and alcohol consumed from the FFQ. We also assessed overall diet quality using the Alternative Healthy Eating Index 2010, where a higher score was associated with reduced risks of cardiovascular disease, diabetes<sup>27, 28</sup>, and colorectal cancer<sup>29</sup>. Smoking status was updated biennially for calculation of pack-years smoked. Physical activity was self-reported with validated questionnaires every 2 to 4 years<sup>30</sup>. A metabolic equivalent of task score (METs) based on energy expenditure was used to assign to each type of physical activity, and the amount of total physical activity was calculated by multiplying the METs by the mean time spent in each activity. We examined TV viewing time as a measure for sedentary behavior because previous studies showed that this specific sedentary behavior was associated with chronic diseases<sup>31</sup> and early-onset CRC<sup>9</sup>. The NHS II participants also regularly provided updated information on regular use of aspirin and other nonsteroidal anti-inflammatory drugs, use of post-menopausal hormone therapy, and family history of CRC among first-degree relatives.

### Ascertainment of CRC

Our primary endpoint was incident early-onset CRC, defined as CRC diagnosed before 50 years of age. We requested written permission to collect medical records and pathology reports from participants who reported having CRC on biennial questionnaires for confirmation of diagnosis. We also identified unreported, lethal CRC cases through family members, the postal system, and the National Death Index. For all deaths due to CRC, we requested consent for medical records acquisition from the next of kin. Physicians who were

blinded to exposure status reviewed medical records to verify CRC diagnosis and recorded histopathologic findings and anatomical location.

### Ascertainment of colorectal adenoma cases

The NHS II participants were asked on each biennial follow-up questionnaire whether they underwent a lower bowel endoscopy (either sigmoidoscopy or colonoscopy), the reasons for endoscopy (whether for routine screening without symptoms or for prior symptoms such as bleeding or abdominal pain), and whether colorectal polyps were diagnosed. Participants who reported a diagnosis of polyp were mailed a consent form requesting permission to obtain and review their medical including endoscopy and pathology records. Study investigators blinded to exposure status reviewed medical records and recorded anatomical location (proximal colon, distal colon, or rectum), subtype (conventional adenoma or serrated polyp), histology for conventional adenoma (tubular, tubulo-villous, or villous adenoma, or adenoma with high-grade dysplasia), number of lesions, and maximum size of the lesion in each patient (large if  $\geq 10$  mm in diameter). Adenomas were defined as high risk if there was any mention of these features: large size, advanced histology (tubulo-villous/villous adenoma or high-grade dysplasia), or presence of  $\geq 3$  adenomas. All other adenomas were defined as low-risk adenomas. Serrated polyps included hyperplastic polyps, sessile serrated polyps with or without cytological dysplasia, and traditional serrated adenomas. When two polyps were diagnosed in one location, we recorded the most advanced lesion, and whenever conventional adenoma and serrated polyp were detected in one location, they were coded as separate endpoints.

### Statistical analysis

We prospectively evaluated the association between total vitamin D intake and risk of early-onset CRC. Person-time was measured from the return of the baseline questionnaire in 1991 until the date of CRC diagnosis, death from any cause, 50<sup>th</sup> birthday, or the end of follow-up (June 2015), whichever came first. We used energy-adjusted vitamin D intake that was calculated from the regression-residual method to minimize variation due to energy intake and related measurement error<sup>32</sup>. To better capture long-term behaviors and nutritional status and reduce within-person variations, we used cumulative averages for lifestyle and dietary factors, including total vitamin D intake. We examined the association between total vitamin D intake and risk of early-onset CRC using Cox proportional hazard models to estimate age- and multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs). The Cox model was stratified by age and year of questionnaire return. Covariates were chosen *a priori* based on established risk factors for traditional CRC<sup>33</sup>. The primary statistical test was a test for linear trend, which was performed using the median of total vitamin D intake category as a continuous variable. We examined potential nonlinear associations using restricted cubic splines<sup>34, 35</sup>.

We also evaluated the association between total vitamin D intake and risk of early-onset conventional adenoma and serrated polyp that occurred at age  $<50$  years among those who underwent at least one lower endoscopy. We restricted the analysis to those who underwent at least one lower endoscopy because polyps are often asymptomatic and only detected during an endoscopy. Once a participant was diagnosed with a polyp or reached

age 50, the subsequent followup periods were not included in the analysis. We used age- and multivariable-adjusted logistic regression models for longitudinal data to account for repeated observations (multiple endoscopies for a participant) to estimate odds ratios (ORs) and 95% CIs. Using proc genmod in SAS, we fitted generalized estimating equation<sup>36</sup>. Covariates were chosen a priori based on established risk factors for CRC<sup>33</sup>, as risk factors for CRC and adenoma are similar<sup>37</sup> and serrated polyp and conventional adenoma share many risk factors<sup>23</sup>.

We performed various stratified and sensitivity analyses. We used the model for predicting plasma 25(OH)D levels developed within our cohort<sup>26</sup> to determine whether predicted 25(OH)D levels are associated with early-onset CRC. We also performed stratified analyses based on anatomical tumor location (colon or rectum) and BMI (BMI <25 kg/m<sup>2</sup> or ≥ 25 kg/m<sup>2</sup>). Different sources of total vitamin D intake (dietary vitamin D or supplemental vitamin D) were evaluated. In addition, to minimize the possibility that undiagnosed CRC may have contributed to total vitamin D intake, we employed lag analyses; we excluded the first 2, 4, and 8 years of follow-up and added 2-, 4-, and 8- year lag period between vitamin D assessment and each follow-up period to address the possibility of changes in behaviors during the preclinical phase and evaluate the period that is etiologically relevant. We performed several stratified analyses for adenomas based on histology, anatomical location (proximal colon, distal colon, or rectum), and reason for endoscopy. For adenomas, we also assessed interaction between continuous total vitamin D intake and potential effect modifiers: BMI (<25 vs. ≥ 25 kg/m<sup>2</sup>), total calcium intake (<1,100 vs. ≥ 1,100 mg/day), physical activity (<15 vs. ≥ 15 METS-hours/week), and smoking status (ever vs. never). We conducted sensitivity analysis for adenomas that occurred at age <45 years. As it could take more than 5 years for an adenoma to develop into cancer, adenomas at age <45 may be more relevant for early-onset CRC.

All statistical analyses were two-sided and P values <0.05 indicated statistical significance. Analyses were performed using SAS 9.4 (SAS Institute, Cary, NC).

## RESULTS

Among the 94,205 women studied, we documented 111 incident cases of early-onset CRC during 1,250,560 person-years of follow-up from 1991 to 2015. The median vitamin D intake was 372 IU/day. Among women younger than age 50, those with higher vitamin D intake tended to have a lower BMI; were less likely to smoke cigarettes, drink alcohol, spend time watching TV, and eat red and processed meat; consumed more dietary fiber, total folate, and total calcium; used more aspirin and multivitamins; and were more likely to be physically active and have a healthy dietary pattern (Table 1).

In the age- and multivariable-adjusted analyses, higher total vitamin D intake was associated with a reduced risk of early-onset CRC (Table 2). In the fully adjusted model, compared with women who consumed <300 IU/day of total vitamin D intake, the HRs were 0.51 (95% CI, 0.30-0.86) for those who consumed 300-<450 IU/day of total vitamin D intake and 0.49 (95% CI, 0.26-0.93) for those who consumed ≥ 450 IU/day of total vitamin D intake (*P* for trend = 0.01) (Table 2). There was no evidence of a nonlinear association (*P* for nonlinearity



= 0.50). The HR per 400 IU/day increase was 0.46 (95% CI, 0.26-0.83) (Table 2). We observed similar risk estimates when we restricted our analysis to participants without a family history of CRC (n = 98 cases) and without a lower endoscopy in the past 10 years (n = 104 cases).

We also evaluated differences in sources of vitamin D intake. Both sources of vitamin D intake were inversely associated with early-onset CRC, with a significant and stronger association observed for dietary vitamin D (HR per 400 IU/day increase, 0.34; 95% CI, 0.15-0.79) than supplemental vitamin D (HR per 400 IU/day increase, 0.77; 95% CI, 0.37-1.62) (Table 3). No significant interaction between dietary vitamin D and supplemental vitamin D was found in the NHS II cohort (*P* for interaction = .81). Among dietary sources, vitamin D from dairy products was the major contributor of this association (HR per 400 IU/day increase, 0.32; 95% CI, 0.12-0.84).

We documented 1,439 newly diagnosed conventional adenomas and 1,878 serrated polyps among 29,186 women aged <50 who had at least one lower endoscopy between 1991 and 2011. Higher total vitamin D intake was associated with a lower risk of early-onset conventional adenoma and suggestively associated with serrated polyp (Table 4). Compared to women who consumed <300 IU of total vitamin D per day, the multivariable-adjusted OR of any conventional adenoma was 0.71 (95% CI, 0.56-0.89) for those who consumed 600 IU/day (*P* for trend = 0.002), while the multivariable-adjusted OR of any serrated polyp for the same comparison was 0.85 (95% CI, 0.70-1.03; *P* for trend = 0.11) (Table 4). There was no evidence of a nonlinear association (*P* for nonlinearity = 0.29 for conventional adenoma and 0.78 for serrated polyp). The ORs per 400 IU/day increase were 0.76 (95% CI, 0.65-0.88) for conventional adenoma and 0.85 (95% CI, 0.75-0.97) for serrated polyp (Table 4).

Stratified analysis by tumor anatomical site showed similar inverse associations between total vitamin D intake and risks of early-onset colon and rectal cancer (Supplementary Table 1). Stratified analysis by BMI suggested that the potential beneficial association of vitamin D intake is not different for those with BMI <25 kg/m<sup>2</sup> compared to those with BMI ≥ 25 kg/m<sup>2</sup> (*P* for interaction = 0.65) (Supplementary Table 2). The results did not largely change when we excluded the first 2, 4, and 8 years of follow-up and added 2-, 4-, and 8-year lag periods between vitamin D intake assessment and each follow-up period (Supplementary Table 3).

We observed that the association between continuous vitamin D intake and CRC risk differed based on age at diagnosis (age <50 versus ≥ 50; *P* for heterogeneity = 0.04). While vitamin D intake was associated with early-onset CRC risk, we could not detect a statistically significant association with risk of CRC diagnosed at or after age 50 possibly due to limited power (Supplementary Table 4).

The predicted 25(OH)D score analysis showed similar results as the main analysis, although it did not reach statistical significance (Supplementary Table 5). For early-onset CRC, the HR per 5-unit increase of predicted score was 0.77 (95% CI, 0.50-1.20) and the HR

comparing the highest versus lowest tertile of predicted score was 0.71 (95% CI, 0.37-1.35; *P* for trend = 0.24) (Supplementary Table 5).

The results remained largely unchanged when we repeated the multivariable analyses additionally adjusting for current multivitamin use (Supplementary Table 6), which is a commonly consumed source of supplemental vitamin D as well as other vitamins and minerals. In addition, as calcium intake may confound the relationship between vitamin D intake and early-onset CRC, we additionally adjusted for total calcium intake in the fully adjusted model (Supplementary Table 7). However, adjusting for calcium did not substantially change our results (HR for early-onset CRC per 400 IU/day increase, 0.48; 95% CI, 0.25-0.93) (Supplementary Table 7).

Higher vitamin D intake was associated with decreased risks of both high- and low-risk conventional adenomas (Supplementary Table 8). By anatomical site, we observed stronger inverse associations between total vitamin D intake and risks of early-onset conventional adenomas in distal colon and rectum compared to those in proximal colon, although the association was statistically significant only for adenoma in distal colon (Supplementary Table 9). The inverse association for serrated polyp in distal colon was statistically significant (multivariable-adjusted OR comparing those with  $\geq 600$  IU/day to  $<300$  IU/day of vitamin D intake, 0.64, 95% CI, 0.48-0.84) and stronger than those observed for proximal colon or rectum (Supplementary Table 9). In the stratified analysis by reason for endoscopy, the inverse association was significant only for participants with conventional adenoma who underwent an endoscopy due to screening rather than symptoms, but the difference was not statistically significant (*P* for interaction = 0.09) (Supplementary Table 10). The results did not largely change for serrated polyps diagnosed before age 45, but there was an attenuation in the association for conventional adenomas diagnosed before age 45 compared to age 50 (Supplementary Table 11). In addition, adjusting for calcium did not substantially change our results for adenomas (Supplementary Table 12). No significant interactions were observed between total vitamin D intake and BMI, total calcium intake, physical activity, and smoking status for conventional adenoma and serrated polyp (all *P* for interaction  $>0.05$ ).

## DISCUSSION

In this cohort of young women, higher total vitamin D intake was associated with a reduced risk of early-onset CRC. This risk reduction was mostly driven by dietary vitamin D, particularly from dairy intake.

There is growing evidence supporting an association between vitamin D and risk and mortality of CRC, but there are minimal data on the association between vitamin D and early-onset CRC. Existing literature suggests that higher 25(OH)D levels are associated with a reduced risk of CRC<sup>38</sup> (mostly diagnosed at or above age 50). In a recent large pooling study of 5,706 cases, a 10 ng/mL increment in circulating 25(OH)D was associated with a 19% lower CRC risk in women (95% CI, 75-0.87) and a 7% lower risk in men (95% CI, 0.86-1.00) (*P* for heterogeneity by sex = 0.008)<sup>39</sup>. However, in the Vitamin D and Omega-3 Trial (VITAL), 2,000 IU/day of vitamin D<sub>3</sub> supplementation was not associated with a



lower risk of CRC (HR, 1.09; 95% CI, 0.73-1.62)<sup>40</sup> A large-scale Mendelian randomization study also found no association between genetically determined 25(OH)D levels and CRC (Odds ratio, 0.92; 95% CI, 0.76-1.10)<sup>41</sup>. The association between vitamin D and CRC could truly be negative as the VITAL and Mendelian randomization studies suggested. However, the power for site-specific cancer analyses in the VITAL trial may have been limited to detect an association, and the follow-up time (median follow-up of 5.3 years) may have been insufficient for a chemopreventive effect. Also, although Mendelian randomization studies provide evidence for a causal relationship, genetically determined 25(OH)D could only partially explain the variance in vitamin D. In the Mendelian randomization study, four single nucleotide polymorphisms were identified, and each explained about 1% of the 25(OH)D variability<sup>41</sup>. In our study, total vitamin D intake was inversely associated with risk of CRC diagnosed before age 50. There was no significant association among participants age  $\geq$  50, possibly due to lack of power or differential effects of vitamin D in different age groups. Whether the association is truly stronger in early-onset CRC than in traditional CRC requires further work in a larger sample.

Total vitamin D intake, especially supplemental vitamin D intake, could have secularly increased over time and affected our results. Prevalence of vitamin D supplement use increased from 4.2% in 1986 to 32.3% in 2006 in the NHS I<sup>42</sup> and 5.1% in 1999 to 19% in 2011 in the National Health and Nutrition Examination Survey<sup>43</sup>. However, we did not see a significant interaction between vitamin D intake and time in our data. In addition, we stratified by age and year of the questionnaire in the Cox model, which controls for confounding by age and secular trends<sup>44</sup>.

Most CRC cases arise from precursor lesions called adenomas through the adenomacarcinoma sequence<sup>20</sup>. Increasing evidence also suggests that serrated polyps represent another precursor lesion for CRC through a different pathway<sup>21-23</sup>. Studying conventional adenomas and serrated polyps diagnosed at age  $<$ 50 as precursors could help understand etiologic contributors to the recent rise in early-onset CRC incidence. In our study, total vitamin D intake was inversely associated with CRC precursors, with a stronger association for conventional adenoma and suggestive inverse association for serrated polyp. Sensitivity analysis for adenomas at age  $<$ 45 did not largely change the results, but the association became statistically insignificant possibly due to lack of power. Consistent results among CRC precursors with larger sample size further support the protective role of vitamin D intake on early-onset CRC.

Previous research suggests that young CRC patients have more tumors in distal colon or rectum whereas older CRC patients have more in proximal colon<sup>45</sup>. Our study found that increased total vitamin D intake was more strongly associated with early-onset conventional adenomas in distal colon and rectum compared to those in proximal colon. Recent clinical trials demonstrated that beneficial role of vitamin D on cancer could differ by BMI, with less effect in those with greater BMI<sup>40, 46</sup>. However, our findings did not explain this trend and should further be explored.

Total oral vitamin D intake does not take into account sunlight exposure, which is the major determinant of 25(OH)D status<sup>47</sup>. Nevertheless, vitamin D intake is an important,

measurable contributor to circulating 25(OH)D levels, and the estimates of intake did predict plasma 25(OH)D levels in a sample of the participants<sup>26</sup>. Moreover, in our study, the association for total vitamin D intake remained even after adjusting for physical activity and TV viewing time, which can potentially reflect sun exposure. Although not statistically significant, the results from predicted 25(OH)D score analysis were similar to the main findings. Vitamin D is suggestively protective of early-onset CRC as the predicted 25(OH)D score not only reflects vitamin D from food intake but also sun exposure and variations from other sources.

Interestingly, our findings were driven by dietary vitamin D rather than supplemental vitamin D. This could be due to chance, but one possible explanation is that dietary vitamin D may capture longterm dietary pattern before 1991 (e.g., diet during adolescence), which could be important for early-onset CRC risk, whereas supplemental vitamin D may not reflect supplemental vitamin D intake before 1991. Another possible explanation is that certain nutrients in multivitamins could offset the beneficial effects of vitamin D. For example, high retinol intake completely thwarted vitamin D's otherwise beneficial role in distal colorectal adenoma risk<sup>48</sup>. However, the mechanisms underlying differences between dietary vitamin D intake and supplemental vitamin D intake are not fully understood.

Potential mechanisms that may explain the inverse association between vitamin D intake and risk of CRC include inhibition of proliferation, migration, invasiveness, and angiogenesis of colon carcinoma cells, and regulation of intestinal immune cells<sup>49</sup>. Increasing evidence suggests that early-onset CRC may be molecularly distinct from traditional CRC. A study that examined Consensus Molecular Subtypes (CMS) found that subtypes significantly differed by age group ( $P = 0.003$ ), with CMS1 being the most common subtype for young patients.<sup>50</sup> In addition, early-onset patients were more likely to present with microsatellite instability and synchronous metastatic disease but less likely to have BRAF V600 mutations<sup>50</sup>. The biological mechanisms pertaining specifically to the association of vitamin D and early-onset CRC require further investigation.

The strengths of our study include the prospective design, the long-term follow-up of approximately 30 years, and repeated measurement of dietary and lifestyle factors. In addition, ages at enrollment were young (ages 25-42 years), which enabled us to investigate early-onset CRC and adenoma prospectively. We also had relatively wide variation in vitamin D intake and detailed information on various risk factors of CRC and adenoma. We were able to minimize the influence of measurement error by using the cumulative average of total vitamin D intake. We acknowledge several limitations in our study. First, despite the large number of participants in our cohorts, we had limited number of early-onset CRC cases ( $n = 111$ ), mainly because early-onset CRC remains relatively rare. However, our results were consistent for conventional adenomas ( $n = 1,439$ ) and serrated polyps ( $n = 1,878$ ), which are CRC precursors. Second, the pool of precursors from which early-onset CRC cases arise from includes all precursors before age 50. Because colonoscopy before age 40 is rare, our sample was skewed to those polyps diagnosed mostly from age 40 to 50. Many of these polyps were likely present for years before detection. Third, we could not distinguish whether the results are consistent across all genetic predispositions. However, most of our cases had no family history of CRC and no lower endoscopy within the past

10 years. We confirmed the protective role of vitamin D intake in sporadic early-onset CRC through the consistent results among participants without a family history of CRC and without a lower endoscopy within the past 10 years. Fourth, although our analyses controlled for key risk factors, our results could be affected by residual and unmeasured confounding. Fifth, our study population consisted of female nurses (mostly white), which could reduce the generalizability of the results.

In conclusion, we found evidence that higher total vitamin D intake is associated with decreased risks of early-onset CRC and precursors. Our results further support that avoiding low vitamin D status is important in younger adults for health and possibly CRC prevention. If confirmed, our findings could potentially lead to recommendations for higher vitamin D intake as an inexpensive, low-risk complement to CRC screening as CRC prevention strategies for adults younger than age 50.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgements:

We would like to thank the participants and staff of the Nurses' Health Study II for their continued contributions, as well as the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, and WY. The authors assume full responsibility for analyses and interpretation of these data.

## Funding:

This work was supported by the U.S. National Institutes of Health grants [U01 CA176726, R01 CA205406, R35 CA197735, R21 CA230873, R03 CA197879, R21 CA222940, R35 CA253185, R37 CA246175, K07 CA218377, R00 CA215314]; by the Department of Defense grant [CA160344]; by the American Cancer Society Mentored Research Scholar Grant [MRS-G-17-220-01-NEC]; and by the Project P Fund. The funders of this study had no role in its design or conduct; in the collection, management, analysis, or interpretation of the data; or in the preparation, review, or approval of the manuscript.

## Abbreviations:

<b>25(OH)D</b>	25-hydroxyvitamin D
<b>BMI</b>	body mass index
<b>CI</b>	confidence interval
<b>CRC</b>	colorectal cancer
<b>FFQ</b>	food frequency questionnaire
<b>HR</b>	hazard ratio
<b>METS</b>	metabolic equivalent of task score
<b>MV</b>	multivariable
<b>NHS II</b>	Nurses' Health Study II

<b>NSAID</b>	non-steroid anti-inflammatory drugs
<b>OR</b>	odds ratio
<b>VITAL</b>	Vitamin D and Omega-3 Trial

## References

1. Siegel RL, Torre LA, Soerjomataram I, et al. Global patterns and trends in colorectal cancer incidence in young adults. *Gut*2019;68:2179–2185. [PubMed: 31488504]
2. Siegel RL, Fedewa SA, Anderson WF, et al. Colorectal Cancer Incidence Patterns in the United States, 1974-2013. *J Natl Cancer Inst*2017;109.
3. Bailey CE, Hu CY, You YN, et al. Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010. *JAMA Surg*2015;150:17–22. [PubMed: 25372703]
4. Siegel RL, Jakubowski CD, Fedewa SA, et al. Colorectal Cancer in the Young: Epidemiology, Prevention, Management. *Am Soc Clin Oncol Educ Book*2020;40:1–14.
5. Pearlman R, Frankel WL, Swanson B, et al. Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer. *JAMA Oncol*2017;3:464–471. [PubMed: 27978560]
6. Chang DT, Pai RK, Rybicki LA, et al. Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features. *Mod Pathol*2012;25:1128–39. [PubMed: 22481281]
7. Mauri G, Sartore-Bianchi A, Russo AG, et al. Early-onset colorectal cancer in young individuals. *Mol Oncol*2019;13:109–131. [PubMed: 30520562]
8. Ballester V, Rashtak S, Boardman L. Clinical and molecular features of young-onset colorectal cancer. *World J Gastroenterol*2016;22:1736–44. [PubMed: 26855533]
9. Nguyen LH, Liu PH, Zheng X, et al. Sedentary Behaviors, TV Viewing Time, and Risk of Young-Onset Colorectal Cancer. *JNCI Cancer Spectr*2018;2:pk073. [PubMed: 30740587]
10. Liu PH, Wu K, Ng K, et al. Association of Obesity With Risk of Early-Onset Colorectal Cancer Among Women. *JAMA Oncol*2019;5:37–44. [PubMed: 30326010]
11. Harnack LJ, Steffen L, Zhou X, et al. Trends in vitamin D intake from food sources among adults in the Minneapolis-St Paul, MN, metropolitan area, 1980-1982 through 2007-2009. *J Am Diet Assoc*2011;111:1329–34. [PubMed: 21872696]
12. Calvo MS, Whiting SJ. Prevalence of vitamin D insufficiency in Canada and the United States: importance to health status and efficacy of current food fortification and dietary supplement use. *Nutr Rev*2003;61:107–13. [PubMed: 12723644]
13. Bowman SA. Beverage choices of young females: changes and impact on nutrient intakes. *J Am Diet Assoc*2002;102:1234–9. [PubMed: 12792618]
14. Feskanich D, Ma J, Fuchs CS, et al. Plasma vitamin D metabolites and risk of colorectal cancer in women. *Cancer Epidemiol Biomarkers Prev*2004;13:1502–8. [PubMed: 15342452]
15. Wu K, Feskanich D, Fuchs CS, et al. A nested case control study of plasma 25-hydroxyvitamin D concentrations and risk of colorectal cancer. *J Natl Cancer Inst*2007;99:1120–9. [PubMed: 17623801]
16. Wactawski-Wende J, Kotchen JM, Anderson GL, et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. *N Engl J Med*2006;354:684–96. [PubMed: 16481636]
17. Otani T, Iwasaki M, Sasazuki S, et al. Plasma vitamin D and risk of colorectal cancer: the Japan Public Health Center-Based Prospective Study. *Br J Cancer*2007;97:446–51. [PubMed: 17622244]
18. Jenab M, Bueno-de-Mesquita HB, Ferrari P, et al. Association between pre-diagnostic circulating vitamin D concentration and risk of colorectal cancer in European populations: a nested case-control study. *Bmj*2010;340:b5500. [PubMed: 20093284]

19. Woolcott CG, Wilkens LR, Nomura AM, et al. Plasma 25-hydroxyvitamin D levels and the risk of colorectal cancer: the multiethnic cohort study. *Cancer Epidemiol Biomarkers Prev*2010;19:130–4. [PubMed: 20056631]
20. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. *Cell*1990;61:759–67. [PubMed: 2188735]
21. Hawkins N, Norrie M, Cheong K, et al. CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. *Gastroenterology*2002;122:1376–87. [PubMed: 11984524]
22. Spring KJ, Zhao ZZ, Karamatic R, et al. High prevalence of sessile serrated adenomas with BRAF mutations: a prospective study of patients undergoing colonoscopy. *Gastroenterology*2006;131:1400–7. [PubMed: 17101316]
23. He X, Wu K, Ogino S, et al. Association Between Risk Factors for Colorectal Cancer and Risk of Serrated Polyps and Conventional Adenomas. *Gastroenterology*2018;155:355–373.e18. [PubMed: 29702117]
24. Yuan C, Spiegelman D, Rimm EB, et al. Validity of a Dietary Questionnaire Assessed by Comparison With Multiple Weighed Dietary Records or 24-Hour Recalls. *Am J Epidemiol*2017;185:570–584. [PubMed: 28338828]
25. Salvini S, Hunter DJ, Sampson L, et al. Food-based validation of a dietary questionnaire: the effects of week-to-week variation in food consumption. *Int J Epidemiol*1989;18:858–67. [PubMed: 2621022]
26. Bertrand KA, Giovannucci E, Liu Y, et al. Determinants of plasma 25-hydroxyvitamin D and development of prediction models in three US cohorts. *Br J Nutr*2012;108:1889–96. [PubMed: 22264926]
27. Chiuve SE, Fung TT, Rimm EB, et al. Alternative dietary indices both strongly predict risk of chronic disease. *J Nutr*2012;142:1009–18. [PubMed: 22513989]
28. McCullough ML, Feskanich D, Stampfer MJ, et al. Diet quality and major chronic disease risk in men and women: moving toward improved dietary guidance. *Am J Clin Nutr*2002;76:1261–71. [PubMed: 12450892]
29. Reedy J, Mitrou PN, Krebs-Smith SM, et al. Index-based dietary patterns and risk of colorectal cancer: the NIH-AARP Diet and Health Study. *Am J Epidemiol*2008;168:38–48. [PubMed: 18525082]
30. Wolf AM, Hunter DJ, Colditz GA, et al. Reproducibility and validity of a self-administered physical activity questionnaire. *Int J Epidemiol*1994;23:991–9. [PubMed: 7860180]
31. Hu FB, Li TY, Colditz GA, et al. Television watching and other sedentary behaviors in relation to risk of obesity and type 2 diabetes mellitus in women. *Jama*2003;289:1785–91. [PubMed: 12684356]
32. Willett W, Stampfer mJ. Total energy intake: implications for epidemiologic analyses. *Am J Epidemiol*1986;124:17–27. [PubMed: 3521261]
33. Keum N, Giovannucci E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. *Nat Rev Gastroenterol Hepatol*2019.
34. Harrell FE Jr., Lee KL, Pollock BG. Regression models in clinical studies: determining relationships between predictors and response. *J Natl Cancer Inst*1988;80:1198–202. [PubMed: 3047407]
35. Durrleman S, Simon R. Flexible regression models with cubic splines. *Stat Med*1989;8:551–61. [PubMed: 2657958]
36. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. *Biometrics*1986;42:121–30. [PubMed: 3719049]
37. Grahn SW, Varma MG. Factors that increase risk of colon polyps. *Clin Colon Rectal Surg*2008;21:247–55. [PubMed: 20011435]
38. Kim H, Giovannucci E. Vitamin D Status and Cancer Incidence, Survival, and Mortality. *Adv Exp Med Biol*2020;1268:39–52. [PubMed: 32918213]
39. McCullough ML, Zoltick ES, Weinstein SJ, et al. Circulating Vitamin D and Colorectal Cancer Risk: An International Pooling Project of 17 Cohorts. *J Natl Cancer Inst*2019;111:158–169. [PubMed: 29912394]

40. Manson JE, Cook NR, Lee IM, et al. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. *N Engl J Med* 2019;380:33–44. [PubMed: 30415629]
41. Dimitrakopoulou VI, Tsilidis KK, Haycock PC, et al. Circulating vitamin D concentration and risk of seven cancers: Mendelian randomisation study. *Bmj* 2017;359:j4761. [PubMed: 29089348]
42. Kim HJ, Giovannucci E, Rosner B, et al. Longitudinal and secular trends in dietary supplement use: Nurses' Health Study and Health Professionals Follow-Up Study, 1986–2006. *J Acad Nutr Diet* 2014;114:436–43. [PubMed: 24119503]
43. Kantor ED, Rehm CD, Du M, et al. Trends in Dietary Supplement Use Among US Adults From 1999–2012. *Jama* 2016;316:1464–1474. [PubMed: 27727382]
44. Zhang X, Keum N, Wu K, et al. Calcium intake and colorectal cancer risk: Results from the nurses' health study and health professionals follow-up study. *Int J Cancer* 2016;139:2232–42. [PubMed: 27466215]
45. Stoffel EM, Murphy CC. Epidemiology and Mechanisms of the Increasing Incidence of Colon and Rectal Cancers in Young Adults. *Gastroenterology* 2020;158:341–353. [PubMed: 31394082]
46. Ng K, Nimeiri HS, McCleary NJ, et al. Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The SUNSHINE Randomized Clinical Trial. *Jama* 2019;321:1370–1379. [PubMed: 30964527]
47. Holick MF. Optimal vitamin D status for the prevention and treatment of osteoporosis. *Drugs Aging* 2007;24:1017–29. [PubMed: 18020534]
48. Oh K, Willett WC, Wu K, et al. Calcium and vitamin D intakes in relation to risk of distal colorectal adenoma in women. *Am J Epidemiol* 2007;165:1178–86. [PubMed: 17379616]
49. Ferrer-Mayorga G, Larriba MJ, Crespo P, et al. Mechanisms of action of vitamin D in colon cancer. *J Steroid Biochem Mol Biol* 2019;185:1–6. [PubMed: 29981368]
50. Willauer AN, Liu Y, Pereira AAL, et al. Clinical and molecular characterization of early-onset colorectal cancer. *Cancer* 2019;125:2002–2010. [PubMed: 30854646]



**What you need to know:****Background and context**

Colorectal cancer incidence among adults younger than age 50 (i.e., early-onset colorectal cancer) has been increasing. As the etiology of early-onset colorectal cancer remains largely unknown, establishing its risk factors is essential to guide prevention.

**New findings**

This large prospective cohort study provides evidence that higher total vitamin D intake is associated with reduced risks of early-onset colorectal cancer and precursors.

**Limitations**

The findings are based on observational data. Further studies are warranted to assess causality.

**Impact**

If confirmed, ensuring adequate vitamin D intake could be recommended as a strategy for potential colorectal cancer prevention for younger adults.

**Table 1.**

Baseline characteristics of person-years according to total vitamin D intake among women younger than age 50, Nurses' Health Study II (NHS II)\*

Characteristic	Total vitamin D intake (IU/day)		
	<300	300-<450	450
Mean total vitamin D intake, IU/day	194	370	647
Types of vitamin D intake			
Dietary vitamin D intake, IU/day	175 (64)	259 (93)	301 (124)
Dairy vitamin D intake, IU/day	80 (55)	143 (90)	170 (115)
Person-years	528107	316264	406189
Age, years	41.9 (5.2)	42.4 (5.1)	41.9 (5.4)
White, %	92	94	93
Height, cm	165 (7)	165 (7)	165 (7)
BMI, kg/m <sup>2</sup>	25.3 (5.6)	24.9 (5.2)	24.7 (5.1)
Family history of colorectal cancer, %	5.6	6.0	5.8
Premenopausal, %	91	91	91
History of diabetes, %	1.9	2.0	2.0
Ever smoker, %	35	32	31
Pack-years among ever smokers	13.4 (10.1)	11.7 (9.2)	11.5 (9.2)
Alcohol intake, g/day	3.6 (6.4)	3.4 (5.7)	3.0 (5.2)
Physical activity, METS-hours/week	20.1 (22.9)	22.9 (24.3)	25.5 (27.7)
TV viewing time, hours/week	9.0 (7.9)	8.6 (7.4)	8.3 (7.5)
Regular aspirin use, %	7.8	9.5	11.4
Regular non-aspirin NSAID use, %	25	25	25
Current use of multivitamins, %	24	49	74
Total energy intake, kcal/day	1798 (525)	1898 (500)	1761 (486)
Red and processed meat intake, servings/week	7.2 (4.4)	6.6 (4.0)	5.5 (3.6)
Dietary fiber intake, g/day	17.8 (4.9)	18.6 (4.9)	19.3 (5.5)
Total folate intake, µg/day	335 (119)	472 (162)	731 (255)
Total calcium intake, mg/day	815 (274)	1089 (300)	1324 (433)
Alternate Healthy Eating Index 2010 <sup>†</sup>	42.0 (9.3)	44.2 (9.4)	46.2 (9.6)

Abbreviations: BMI, body mass index; METS, metabolic equivalent of task score; NSAID, nonsteroid anti-inflammatory drugs.

\* All values except for age have been directly standardized to age distribution (in 5-year age group) of the participants. For continuous variables, mean (SD) was presented.

<sup>†</sup>Without alcohol intake.

**Table 2.**

Total vitamin D intake and risk of early-onset CRC, NHS II 1991–2015

Early-onset (Age <50)	Cases / Person-years	HR (95% CI)		
		Age-adjusted model	MV-adjusted model 1*	MV-adjusted model 2†
<b>Total vitamin D intake (IU/day)</b>				
<300	64 / 528107	1 [Ref]	1 [Ref]	1 [Ref]
300–<450	20 / 316264	0.52 (0.31, 0.86)	0.51 (0.31, 0.86)	0.51 (0.30, 0.86)
450	27 / 406189	0.57 (0.36, 0.91)	0.56 (0.35, 0.88)	0.49 (0.26, 0.93)
P for trend§		0.01	0.01	0.01
Per 400 IU/day increase		0.61 (0.41, 0.91)	0.59 (0.39, 0.89)	0.46 (0.26, 0.83)

Abbreviations: CRC, colorectal cancer; HR, hazard ratio; CI, confidence interval; MV, multivariable

\* Additionally adjusted for nondietary factors: White (yes/no), height (continuous), body mass index (continuous), smoking pack-years (continuous), physical activity (continuous), TV viewing time (continuous), alcohol intake (continuous), regular use of aspirin (yes/no), nonsteroidal anti-inflammatory drug use (yes/no), family history of colorectal cancer (yes/no), and history of lower endoscopy within the past 10 years (yes/no).

† Additionally adjusted for dietary intake (total energy, red/processed meat, dietary fiber, total folate, and Alternate Healthy Eating Index 2010, continuous)

§ Calculated using the median of each total vitamin D intake category as a continuous variable

**Table 3.**

Sources of vitamin D intake and risk of early-onset (age<50) CRC, NHS II 1991-2015

Early-onset (Age <50)	Cases / Person-years	HR (95% CI)		
		Age-adjusted model	MV-adjusted model 1*	MV-adjusted model 2†
<b>Dietary vitamin D</b>				
<b>Vitamin D intake (IU/day)</b>				
<150	34 / 271713	I [Ref]	I [Ref]	I [Ref]
150-<300	59 / 662809	0.75 (0.49, 1.14)	0.74 (0.48, 1.14)	0.75 (0.48, 1.17)
300	18 / 316038	0.52 (0.29, 0.92)	0.50 (0.28, 0.90)	0.50 (0.27, 0.93)
P for trend§		0.02	0.02	0.03
Per 400 IU/day increase		0.36 (0.16, 0.80)	0.34 (0.15, 0.76)	0.34 (0.15, 0.79)
<b>Supplemental vitamin D</b>				
<b>Vitamin D intake (IU/day)</b>				
<150	78 / 793230	I [Ref]	I [Ref]	I [Ref]
150-<300	21 / 245405	0.87 (0.53, 1.42)	0.86 (0.53, 1.40)	0.90 (0.51, 1.60)
300	12 / 211925	0.64 (0.35, 1.17)	0.63 (0.34, 1.17)	0.64 (0.28, 1.45)
P for trend§		0.13	0.13	0.30
Per 400 IU/day increase		0.74 (0.45, 1.20)	0.73 (0.44, 1.19)	0.77 (0.37, 1.62)

Abbreviations: CRC, colorectal cancer; HR, hazard ratio; CI, confidence interval; MV, multivariable

\* Additionally adjusted for nondietary factors: White (yes/no), height (continuous), body mass index (continuous), smoking pack-years (continuous), physical activity (continuous), TV viewing time (continuous), alcohol intake (continuous), regular use of aspirin (yes/no), nonsteroidal antiinflammatory drug use (yes/no), family history of colorectal cancer (yes/no), and history of lower endoscopy within the past 10 years (yes/no).

† Additionally adjusted for dietary intake (total energy, red/processed meat, dietary fiber, total folate, and Alternate Healthy Eating Index 2010, continuous)

§ Calculated using the median of each vitamin D intake category as a continuous variable

**Table 4.** Total vitamin D intake and risk of early-onset conventional adenoma and serrated polyp, NHS II 1991-2011

Early-onset (Age <50)	No. of cases	OR (95% CI)		
		Age-adjusted model <sup>*</sup>	MV-adjusted model <sup>**</sup>	MV-adjusted model 2 <sup>†</sup>
<b>Any conventional adenoma</b>				
<b>Total vitamin D intake (IU/day)</b>				
<300	589	I[Ref]	I[Ref]	I[Ref]
300-<450	390	0.85 (0.75, 0.97)	0.87 (0.76, 0.99)	0.83 (0.71, 0.96)
450-<600	258	0.85 (0.73, 0.99)	0.87 (0.75, 1.02)	0.80 (0.66, 0.97)
600	202	0.77 (0.65, 0.91)	0.80 (0.68, 0.94)	0.71 (0.56, 0.89)
P for trend <sup>§</sup>		0.001	0.01	0.002
Per 400 IU/day increase		0.82 (0.74, 0.92)	0.85 (0.76, 0.94)	0.76 (0.65, 0.88)
<b>Any serrated polyp</b>				
<b>Total vitamin D intake (IU/day)</b>				
<300	719	I[Ref]	I[Ref]	I[Ref]
300-<450	518	0.94 (0.84, 1.06)	0.96 (0.86, 1.08)	0.91 (0.80, 1.04)
450-<600	360	0.98 (0.86, 1.12)	1.02 (0.89, 1.17)	0.93 (0.79, 1.09)
600	281	0.88 (0.77, 1.02)	0.94 (0.81, 1.08)	0.85 (0.70, 1.03)
P for trend <sup>§</sup>		0.14	0.54	0.11
Per 400 IU/day increase		0.91 (0.84, 1.00)	0.95 (0.87, 1.03)	0.85 (0.75, 0.97)

Abbreviations: OR, odds ratio; CI, confidence interval; MV, multivariable

<sup>\*</sup> Adjusted for age, time period of endoscopy, time since most recent endoscopy, number of reported endoscopies, and reason for current endoscopy.

<sup>\*\*</sup> Additionally adjusted for nondietary factors: White (yes/no), height (continuous), body mass index (in quintiles), alcohol intake (never, 0.1-4.9, 5-14.9, 15+ g/d), smoking (never, 0.1-4.9, 5-19.9, 20-39.9, 40+ pack-years), regular use of aspirin (yes/no), regular use of NSAIDs (yes/no), physical activity (METS in quintiles), TV viewing time (in quintiles), and family history of colorectal cancer (yes/no).

<sup>†</sup> Additionally adjusted for dietary intake (total energy intake, red and processed meat intake, dietary fiber intake, total folate intake, and Alternate Healthy Eating Index (AHEI)-2010, in quintiles).

<sup>§</sup> Calculated using the median of each total vitamin D intake category as a continuous variable